Clinical Trial Update: An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities

View source ↗

Summary

Expanded access program to provide Nintedanib to patients with non-IPF interstitial lung disease who have no alternative treatment possibilities, supported by m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease

Drugs mentioned

• OFEV (Nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Lung Diseases, Interstitial | Status: APPROVED_FOR_MARKETING